249 related articles for article (PubMed ID: 27864214)
1. Vasculitic neuropathy induced by pembrolizumab.
Aya F; Ruiz-Esquide V; Viladot M; Font C; Prieto-González S; Prat A; Arance A
Ann Oncol; 2017 Feb; 28(2):433-434. PubMed ID: 27864214
[No Abstract] [Full Text] [Related]
2. Drug-associated vasculitis occurring after treatment with pembrolizumab.
Tolaymat OA; Pinkston O; Wang B; Schenk WB; Joseph RW; Mergo PJ; Berianu F
Rheumatology (Oxford); 2019 Aug; 58(8):1501-1503. PubMed ID: 30892627
[No Abstract] [Full Text] [Related]
3. A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma.
Igari S; Yamamoto M; Kikuchi N; Ohtsuka M; Yamamoto T
An Bras Dermatol; 2024; 99(3):450-451. PubMed ID: 38307808
[No Abstract] [Full Text] [Related]
4. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
5. Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma.
Stauner CT; Drexler K; Berneburg M; Haferkamp S
J Dtsch Dermatol Ges; 2018 Nov; 16(11):1376-1378. PubMed ID: 30299577
[No Abstract] [Full Text] [Related]
6. Pembrolizumab-Associated CD8
Baldauf MC; Kapauer M; Joerger M; Flatz L; Rodriguez R; Frank S; Felbecker A; Hartmann-Fussenegger S; Hundsberger T
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33824184
[No Abstract] [Full Text] [Related]
7. An Unusual Case of Synchronous Metastatic Melanomas With Differing Response to Pembrolizumab.
Doolan BJ; McLean C; Mar V; Moore M
J Oncol Pract; 2019 Mar; 15(3):159-160. PubMed ID: 30861362
[No Abstract] [Full Text] [Related]
8. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
9. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
10. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
[No Abstract] [Full Text] [Related]
11. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
Haddox CL; Shenoy N; Shah KK; Kao JC; Jain S; Halfdanarson TR; Wijdicks EF; Goetz MP
Ann Oncol; 2017 Mar; 28(3):673-675. PubMed ID: 27993808
[No Abstract] [Full Text] [Related]
13. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
14. Diffuse Hepatic Infiltration by Metastatic Melanoma.
Velázquez HE; Castro-Alonso FJ; Bourlon C; Gabutti A; Gallegos C; Bourlon MT
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365754
[No Abstract] [Full Text] [Related]
15. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
16. Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
Algaeed M; Mukharesh L; Heinzelmann M; Kaminski HJ
Neurology; 2018 Oct; 91(14):e1365-e1367. PubMed ID: 30275130
[No Abstract] [Full Text] [Related]
17. Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars.
McKenna MC; Molloy K; Crowther S; Feeney J; Gillis A; Connolly M; Kelleher F
J Oncol Pract; 2018 Mar; 14(3):200-201. PubMed ID: 29300520
[No Abstract] [Full Text] [Related]
18. Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
Diamantopoulos PT; Tsatsou K; Benopoulou O; Anastasopoulou A; Gogas H
J Immunother; 2017; 40(6):221-223. PubMed ID: 28498142
[TBL] [Abstract][Full Text] [Related]
19. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
20. Pembrolizumab-Induced Alopecia Areata.
Elshimy N; Blakeway E; Mitra A
Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
